Sleep study for infant hemangioma drug halted early
NCT ID NCT05479123
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at how often infants with hemangiomas wake up at night when taking propranolol either two or three times a day. It aimed to see if a three-times-daily schedule caused less sleep disruption. The trial was terminated early, so the findings are incomplete.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- propranolol
- What this could lead to
- If successful, this could help doctors choose a dosing schedule that causes fewer sleep disruptions for infants taking propranolol for hemangiomas.
- What could go wrong
- The study was terminated early, so results are limited. It is a small, Phase 4 trial focused on a side effect, not on curing the condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFANTILE HEMANGIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Texas Health Science Center at Houston
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.